Live feed07:00:00·222dPRReleasevia QuantisnowAtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant DepressionByQuantisnow·Wall Street's wire, on your screen.ATAI· AtaiBeckley Inc.Health Care